The Scale Of What's At Stake

According to research published by Fortune Business Insights, the AI healthcare market was valued at $39.3 billion in 2025 and is projected to exceed $1 trillion by 2034. A Grand View Research report projected that the GenAI segment within healthcare alone would reach $28 billion by 2033. The raw material powering this growth is the intellectual output of healthcare publishers and clinical researchers.

AI-generated summaries now appear at the top of medical and clinical search results. Traffic to specialist health publications has collapsed as users receive synthesized answers drawn from publisher content without ever visiting the source. For healthcare publishers whose ad revenue depends on audience reach, this is existential. The beneficiaries of their content aren't paying for it. The creators are absorbing all of the loss.

Healthcare Content Isn't Generic

Medical content isn't interchangeable with general publishing. A clinical review article subjected to rigorous peer review carries additional legal and clinical weight. When AI models train on this content and reproduce its substance without attribution or compensation, the damage is both financial and epistemic.

Medical AI that trains on unverified or outdated clinical data can propagate errors with direct consequences for patient outcomes. The question of who created the training data—and whether it was accurate and consented to—isn't merely an ethical nicety. It's a patient safety issue.

Publishers Must Reclaim Control

Part of the problem is structural. Healthcare publishers have historically lacked the infrastructure to understand the full value of their content—who's consuming it and how it's being monetized downstream. Without that visibility, negotiating from a position of strength is nearly impossible.

Healthcare publishers can't afford to remain passive observers as AI adoption accelerates. Reclaiming control begins with establishing clear licensing frameworks that define how content can be accessed, used and compensated. Publishers should also strengthen content governance through crawler management, access controls and greater visibility into how their intellectual property is being consumed.​

Industry collaboration will be equally important. Establishing common standards around attribution, licensing and responsible use of clinical content can help publishers negotiate from a position of greater strength as AI ecosystems continue to evolve.​

Commercial innovation has a role to play as well. Better audience intelligence, content analytics and monetization infrastructure can help publishers understand and capture the value of their content. Purpose-built healthcare advertising platforms can support these efforts, but they're only one part of a broader strategy that also includes licensing, governance, transparency and industry-wide cooperation.​

The Moment To Act Is Now

More than four in five physicians surveyed for a 2026 American Medical Association report said they now use AI tools in clinical practice—a figure that more than doubled from 2023. The healthcare system is being reshaped faster than most institutions appreciate. The content that trains these systems and shapes their decisions at the point of care deserves a sustainable economic foundation.

Healthcare publishers hold the most valuable, rigorously regulated and clinically credible content in the world. The question is whether the industry will develop the tools, data infrastructure and collective resolve to ensure the AI revolution doesn't come entirely at their expense. Degrading the economics of medical publishing degrades the pipeline of accurate clinical knowledge on which safe AI ultimately depends.

Algorithms alone won't define the future of AI. It will be defined by how fairly we treat the people and institutions whose knowledge makes those algorithms possible.

Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?